Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT01812707

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01812707
Other papers using this trial's data
  • Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies) The American journal of cardiology, 2016-07-01 DOI, PubMed 27184170

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01812707. Randomized; double masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-09-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan
Condition
Hypercholesterolemia
Intervention (Drug)
Alirocumab
Intervention (Drug)
Placebo (for alirocumab)
Intervention (Drug)
Atorvastatin
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01812707
Content hash
a593541547e108eb249a414c6b4f93078a36a32e91c0865d6a56ad091908a6cc